Literature DB >> 20610624

miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer.

Shuangni Yu1, Zhaohui Lu, Changzheng Liu, Yunxiao Meng, Yihui Ma, Wugan Zhao, Jianping Liu, Jia Yu, Jie Chen.   

Abstract

Therapeutic applications of microRNA (miRNA) in KRAS-driven pancreatic cancers might be valuable, but few studies have explored this area. Here, we report that miR-96 directly targets the KRAS oncogene and functions as a tumor-suppressing miRNA in pancreatic cancer cells. Ectopic expression of miR-96 through a synthetic miRNA precursor inhibited KRAS, dampened Akt signaling, and triggered apoptosis in cells. In human clinical specimens, miR-96 was downregulated or deleted where an association with KRAS elevations was observed. In vitro and in vivo assays established that miR-96 decreased cancer cell invasion and migration and slowed tumor growth in a manner associated with KRAS downregulation. Our findings identify miR-96 as a potent regulator of KRAS, which may provide a novel therapeutic strategy for treatment of pancreatic cancer and other KRAS-driven cancers. (c)2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20610624     DOI: 10.1158/0008-5472.CAN-09-4531

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  156 in total

1.  Alteration in miRNA gene expression pattern in acute promyelocytic leukemia cell induced by arsenic trioxide: a possible mechanism to explain arsenic multi-target action.

Authors:  Seyed H Ghaffari; Davood Bashash; Majid Zaki Dizaji; Ardeshir Ghavamzadeh; Kamran Alimoghaddam
Journal:  Tumour Biol       Date:  2011-11-10

Review 2.  MicroRNA-Based Therapeutic Strategies for Targeting Mutant and Wild Type RAS in Cancer.

Authors:  Sriganesh B Sharma; John Michael Ruppert
Journal:  Drug Dev Res       Date:  2015-08-18       Impact factor: 4.360

3.  MiR-197 induces Taxol resistance in human ovarian cancer cells by regulating NLK.

Authors:  Dongling Zou; Dong Wang; Rong Li; Ying Tang; Li Yuan; Xingtao Long; Qi Zhou
Journal:  Tumour Biol       Date:  2015-04-02

Review 4.  Prospects of miRNA-based therapy for pancreatic cancer.

Authors:  Priya Pai; Satyanarayana Rachagani; Chandrakanth Are; Surinder K Batra
Journal:  Curr Drug Targets       Date:  2013-09       Impact factor: 3.465

Review 5.  Targeting microRNAs in pancreatic cancer: microplayers in the big game.

Authors:  Sheema Khan; Deepak Kumar; Meena Jaggi; Subhash C Chauhan
Journal:  Cancer Res       Date:  2013-11-07       Impact factor: 12.701

6.  Iodine-125 irradiation inhibits invasion of gastric cancer cells by reactivating microRNA-181c expression.

Authors:  Yong Yang; Zhen-Huan Ma; Xiao-Gang Li; Wan-Fu Zhang; Jia Wan; Ling-Juan Du; Guo-Jian Li; Guo-Kai Yang; Ping Lu
Journal:  Oncol Lett       Date:  2016-08-17       Impact factor: 2.967

7.  miR-1298 Inhibits Mutant KRAS-Driven Tumor Growth by Repressing FAK and LAMB3.

Authors:  Ying Zhou; Jason Dang; Kung-Yen Chang; Edwin Yau; Pedro Aza-Blanc; Jorge Moscat; Tariq M Rana
Journal:  Cancer Res       Date:  2016-10-01       Impact factor: 12.701

8.  Overexpressed let-7a inhibits glioma cell malignancy by directly targeting K-ras, independently of PTEN.

Authors:  Xi-Rui Wang; Hui Luo; Hai-Lin Li; Lei Cao; Xie-Feng Wang; Wei Yan; Ying-Yi Wang; Jun-Xia Zhang; Tao Jiang; Chun-Sheng Kang; Ning Liu; Yong-Ping You
Journal:  Neuro Oncol       Date:  2013-10-03       Impact factor: 12.300

9.  Expression of miR-21, miR-31, miR-96 and miR-135b is correlated with the clinical parameters of colorectal cancer.

Authors:  Xin Min Xu; Jian Chang Qian; Zhou Lu Deng; Zhe Cai; Tao Tang; Peng Wang; Ke Hua Zhang; Jian-Ping Cai
Journal:  Oncol Lett       Date:  2012-05-14       Impact factor: 2.967

10.  MiR-96 downregulates RECK to promote growth and motility of non-small cell lung cancer cells.

Authors:  Haizhou Guo; Qianping Li; Weihao Li; Tianliang Zheng; Song Zhao; Zhangsuo Liu
Journal:  Mol Cell Biochem       Date:  2014-01-29       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.